Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Lipoprotein(a) (Lp(a)) and its measurement, structure and function, the impact of ethnicity and environmental factors, epidemiological and genetic associations with vascular disease, and new prospects in drug development have been extensively examined throughout this Thematic Review series on Lp(a). Studies suggest that the kidney has a role in Lp(a) catabolism, and that Lp(a) levels are increased in association with kidney disease only for people with large apo(a) isoforms. By contrast, in those patients with large protein losses, as in the nephrotic syndrome and peritoneal dialysis, Lp(a) is increased irrespective of apo(a) isoform size. Such acquired abnormalities can be reversed by kidney transplantation or remission of nephrosis. In this Thematic review we focus on the relationship between Lp(a), chronic kidney disease and risk of cardiovascular events.

Original publication

DOI

10.1194/jlr.R083626

Type

Journal article

Journal

J Lipid Res

Publication Date

29/01/2018

Keywords

Atherosclerosis, Epidemiology, Kidney, Lipoproteins, Renal disease